Last reviewed · How we verify

S-ketamine infusion inpatient setting

Erasmus Medical Center · Phase 1 active Small molecule

S-ketamine infusion inpatient setting is a Small molecule drug developed by Erasmus Medical Center. It is currently in Phase 1 development. Also known as: ketamine, esketamine.

At a glance

Generic nameS-ketamine infusion inpatient setting
Also known asketamine, esketamine
SponsorErasmus Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about S-ketamine infusion inpatient setting

What is S-ketamine infusion inpatient setting?

S-ketamine infusion inpatient setting is a Small molecule drug developed by Erasmus Medical Center.

Who makes S-ketamine infusion inpatient setting?

S-ketamine infusion inpatient setting is developed by Erasmus Medical Center (see full Erasmus Medical Center pipeline at /company/erasmus-medical-center).

Is S-ketamine infusion inpatient setting also known as anything else?

S-ketamine infusion inpatient setting is also known as ketamine, esketamine.

What development phase is S-ketamine infusion inpatient setting in?

S-ketamine infusion inpatient setting is in Phase 1.

Related